文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

预防COVID-19的药物:活系统评价与网络荟萃分析

Prophylaxis against covid-19: living systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2021-04-26

分析显示,在16种被分析的预防药物中,无一能提供令人信服的证据证明可降低实验室确诊SARS-CoV-2感染风险;对于住院和死亡结局,也没有任何预防药物与标准治疗或安慰剂存在差异。羟氯喹和维生素C联合锌可能增加导致停药的不良反应风险。

要点

  • 16种被分析的预防药物均无令人信服的证据表明可降低SARS-CoV-2感染风险。
  • 对于住院和死亡结局,没有任何预防药物优于标准治疗或安慰剂。
  • 羟氯喹和维生素C联合锌可能增加导致停药的不良反应风险。

核心结论

  • 目前证据多为极低确定性,未来评估预防药物的研究可能改变对SARS-CoV-2感染、住院和死亡结局的结果。
  • 羟氯喹和维生素C联合锌可能增加不良反应。

研究设计与样本

  • 活系统评价与网络荟萃分析(NMA)。
  • 数据来源为世界卫生组织COVID-19数据库,涵盖截至2022年3月4日的全球多语种COVID-19文献。
  • 纳入随机试验,将COVID-19风险人群分配至预防用药或无预防(标准治疗或安慰剂)。

主要发现

  • 在16种被分析的预防药物中,无一能提供令人信服的证据证明可降低实验室确诊SARS-CoV-2感染风险。
  • 对于住院和死亡结局,没有任何预防药物与标准治疗或安慰剂存在差异。
  • 羟氯喹导致停药的不良反应风险差异为每1000人增加6例(95%可信区间2至10例)。
  • 维生素C联合锌导致停药的不良反应风险差异为每1000人增加69例(95%可信区间47至90例),中等确定性证据。

关键数值与推荐

  • 羟氯喹导致停药的风险差异:每1000人增加6例(95%CrI 2至10例)。
  • 维生素C联合锌导致停药的风险差异:每1000人增加69例(95%CrI 47至90例),中等确定性证据。

临床怎么用

  • 不推荐使用羟氯喹或维生素C联合锌进行COVID-19预防,因其可能增加导致停药的不良反应。
  • 对于其他预防药物,目前尚无令人信服的证据支持其降低SARS-CoV-2感染、住院或死亡风险。

局限性

  • 多数证据的确定性为极低,未来研究可能改变结果。
  • 本系统评价未注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UPDATES: This is the second version (first update) of the living systematic review, replacing the previous version (available as a data supplement). When citing this paper please consider adding the version number and date of access for clarity. OBJECTIVE: To determine and compare the effects of drug prophylaxis on severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (covid-19). DESIGN: Living systematic review and network meta-analysis (NMA). DATA SOURCES: World Health Organization covid-19 database, a comprehensive multilingual source of global covid-19 literature to 4 March 2022. STUDY SELECTION: Randomised trials in which people at risk of covid-19 were allocated to prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles. METHODS: After duplicate data abstraction, we conducted random-effects bayesian network meta-analysis. We assessed risk of bias of the included studies using a modification of the Cochrane risk of bias 2.0 tool and assessed the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. RESULTS: The second iteration of this living NMA includes 32 randomised trials which enrolled 25 147 participants and addressed 21 different prophylactic drugs; adding 21 trials (66%), 18 162 participants (75%) and 16 (76%) prophylactic drugs. Of the 16 prophylactic drugs analysed, none provided convincing evidence of a reduction in the risk of laboratory confirmed SARS-CoV-2 infection. For admission to hospital and mortality outcomes, no prophylactic drug proved different than standard care or placebo. Hydroxychloroquine and vitamin C combined with zinc probably increase the risk of adverse effects leading to drug discontinuation—risk difference for hydroxychloroquine (RD) 6 more per 1000 (95% credible interval (CrI) 2 more to 10 more); for vitamin C combined with zinc, RD 69 more per 1000 (47 more to 90 more), moderate certainty evidence. CONCLUSIONS: Much of the evidence remains very low certainty and we therefore anticipate future studies evaluating drugs for prophylaxis may change the results for SARS-CoV-2 infection, admission to hospital and mortality outcomes. Both hydroxychloroquine and vitamin C combined with zinc probably increase adverse effects. SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol established a priori is included as a supplement. FUNDING: This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321).

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021. PMID: 33903131. doi:10.1136/bmj.n949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。